Revolution Medicines Stock Forecast
NASDAQ: RVMDHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
Market open · Delayed 15 min · as of Oct 9, 10:39 AM ET
RVMD analyst consensus
Consensus (24 analysts)
strong_buy
Avg. price target
$258.84+36.96%
- Strong buy 5
- Buy 18
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 24 Wall Street analysts covering Revolution Medicines (2026-10-07), 23 rate the stock a buy or strong buy, 1 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "strong_buy". The average 12-month price target is $258.84, with a high estimate of $320.00 and a low estimate of $179.00. The average target implies upside of 37.0% from the current price of $188.99.
The spread between the highest and lowest targets is 78.8%, a relatively narrow range. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for RVMD.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 5 | 21% |
| Buy | 18 | 75% |
| Hold | 1 | 4% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-07.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $179.00 | -5.29% |
| Average target | $258.84 | +36.96% |
| High target | $320.00 | +69.32% |